BioMarin Pharmaceuticalvs.Regeneron
BMRN vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 6.2× larger than BioMarin Pharmaceutical by market cap; Regeneron trades at the lower P/E (19.0 vs 183.0).
Side by side
| BMRN | REGN | |
|---|---|---|
| Market cap | $13.4B | $82.2B |
| Price | $66.12 | $833.56 |
| Today | +1.6% | +0.6% |
| Return YTD | +9.5% | +7.3% |
| Return 1Y | +11.1% | +40.5% |
| P/E | 183.0 | 19.0 |
| P/S | 3.9 | 5.3 |
| P/B | 2.1 | 2.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More BMRN & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BMRN and REGN sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →